Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV005270246 | SCV005933547 | uncertain significance | not specified | 2025-03-14 | criteria provided, single submitter | clinical testing | The c.65A>C (p.N22T) alteration is located in exon 2 (coding exon 2) of the SAMD13 gene. This alteration results from a A to C substitution at nucleotide position 65, causing the asparagine (N) at amino acid position 22 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |